Last updated: May 16, 2026
This page documents how analyses on HealthDataConsortium.org are produced, funded, and governed. It serves as both a methodological reference and a comprehensive disclosure of financial and editorial relationships.
Analytical Methodology
Source Hierarchy
Analyses prioritize sources in the following order:
Tier 1 — Primary Clinical Evidence: Randomized controlled trials published in peer-reviewed journals, systematic reviews, and meta-analyses. These sources carry the highest evidentiary weight and are cited by DOI or PubMed identifier when available.
Tier 2 — Regulatory and Institutional Sources: FDA communications, NIH databases, clinical practice guidelines from recognized medical societies, and published prescribing information.
Tier 3 — Structured Market Data: Manufacturer disclosures, published pricing, terms of service documentation, pharmacy licensing records, and verifiable company filings.
Tier 4 — Supplementary Context: Consumer outcome reports, practitioner observations, and traditional use documentation. These sources provide context but are not treated as evidence of efficacy or safety.
Sources are cited within analyses. When a claim cannot be traced to a Tier 1 or Tier 2 source, the evidentiary limitation is stated explicitly.
Evaluation Frameworks
Supplement Analysis: Ingredient evidence scoring, dosage adequacy assessment, claim verification, formulation logic evaluation, and comparative market positioning. Each dimension is assessed independently to prevent halo effects from strong performance in one area masking weakness in another.
Telehealth Platform Evaluation: Clinical protocol rigor, pricing architecture, pharmacy compliance, medication classification accuracy, provider credentialing, and consumer protection terms. Platforms are assessed against standardized criteria rather than ranked against each other.
Protocol Analysis: Mechanism tracing through published literature, outcome quantification from available data, adverse effect documentation, and gap analysis between popular presentation and clinical evidence.
Limitations
This publication analyzes publicly available information and published research. It does not conduct original clinical trials, perform laboratory testing on products, or have access to proprietary formulation data beyond what manufacturers disclose on product labels.
When finished-product clinical trials do not exist (which is common for dietary supplements), analyses evaluate individual ingredients rather than the formulated product. This distinction is stated in every applicable analysis.
Regulatory Framing — Supplements (DSHEA)
Dietary supplements analyzed on this site are regulated under the Dietary Supplement Health and Education Act of 1994 (DSHEA), not as drugs. This regulatory context shapes how the publication describes evidence and claims:
Statements about dietary supplements published on this site have not been evaluated by the Food and Drug Administration. Dietary supplements are not intended to diagnose, treat, cure, or prevent any disease.
The publication's evaluations describe ingredient evidence, dosage adequacy, formulation logic, claim accuracy, and comparative market positioning. Where research suggests potential structure or function effects, language such as “may support,” “is associated with,” or “clinical research suggests” is used to convey appropriate uncertainty. Absolute efficacy language is not used because the underlying evidence does not support it.
Individual results vary. Readers managing health conditions should consult qualified healthcare providers before starting, modifying, or discontinuing any supplement regimen.
Regulatory Framing — Compounding Medications
Many telehealth platforms covered in published evaluations dispense compounded medications rather than commercially manufactured FDA-approved finished drug products. This applies particularly to compounded GLP-1 weight management medications (semaglutide, tirzepatide), compounded testosterone preparations, compounded PDE5 inhibitors, and compounded peptide preparations.
Compounded medications are not FDA-approved finished drug products. They are prepared by licensed 503A compounding pharmacies under a valid physician prescription and are not subject to the same pre-market safety, efficacy, and quality review process as commercially manufactured FDA-approved drugs. This does not indicate unsafe products from licensed compounding pharmacies operating under proper oversight, but the distinction is legally and clinically meaningful.
503A pharmacies operate under state-level oversight and prepare medications for individual patients based on specific prescriptions. 503B outsourcing facilities operate under FDA oversight including current Good Manufacturing Practice (cGMP) requirements and may prepare medications in larger quantities without individual prescriptions.
Telehealth platform evaluations published on this site identify when a platform dispenses compounded medications, specify the compounding classification (503A or 503B) where verifiable, and note the regulatory implications. Verify the compounding pharmacy's licensing status with your state pharmacy board before ordering.
Financial Disclosures
Revenue Model
HealthDataConsortium.org generates revenue through paid link relationships. Certain paid links within published analyses direct readers to product or service websites. If a reader completes a purchase through these paid links, this publication may receive a commission at no additional cost to the reader.
This constitutes a material financial relationship between this publication and the companies whose products are analyzed. This disclosure is made in compliance with the Federal Trade Commission's Endorsement Guides (16 CFR Part 255).
What Paid Link Relationships Do Not Influence
Paid link commission structures do not determine which products or platforms are selected for analysis. Selection is based on reader interest, search demand, analytical merit, and category significance.
Paid link commissions do not influence analytical conclusions, framework scoring, or comparative assessments. Analyses have produced critical findings for products with active paid link relationships and favorable findings for products without paid link relationships.
No manufacturer, platform, or brand has editorial review rights, pre-publication access, or veto authority over any content published on this site.
Individual Analysis Attribution
Each analysis concludes with an attribution block that includes: authorship credit, date of publication and most recent revision, financial disclosure statement, and a link to this methodology page. This end-of-article placement ensures the disclosure accompanies the specific content it relates to.
Editorial Independence
HealthDataConsortium.org is not funded by any pharmaceutical company, supplement manufacturer, telehealth platform, or government entity. It operates as a commercially funded independent publication.
No individual or organization outside the publication's own analysts has influence over what is published, how analyses are scored, or what conclusions are reached.
Health Content Disclaimer
All content on this site is produced for informational and educational purposes. It does not constitute medical advice, clinical recommendations, or diagnostic guidance.
The analysts contributing to this publication are health researchers. They are not physicians, pharmacists, nurses, dietitians, or any category of licensed healthcare practitioner.
This domain was previously operated by the Health Data Consortium, a 501(c)(3) nonprofit whose tax-exempt status was revoked in 2016. The current publication has no affiliation with that organization.
Readers managing health conditions should consult qualified healthcare providers before making decisions about supplements, medications, or wellness programs. The analyses published here are designed to support informed decision-making — not replace professional clinical guidance.
Corrections
If any published analysis contains a factual error, misrepresented study finding, or outdated information, contact the HDC team through the Contact page and select “Editorial Correction” as the inquiry type. Corrections are published promptly with documentation of what changed and why.
HealthDataConsortium.org is an independent analytical publication. It is not a medical practice, nonprofit organization, or government entity. This domain was previously operated by a 501(c)(3) nonprofit whose tax-exempt status was revoked in 2016; the current publication has no affiliation with that organization. Content is informational only — not medical advice. Some links on this site are paid links.